Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase

被引:3
|
作者
Schultz, Thomas E. [1 ,2 ]
Lynch, Alia C. [2 ]
机构
[1] Ohio State Univ, James Canc Hosp, Room C150,460 W 10th Ave, Columbus, OH 43210 USA
[2] Univ Virginia Hlth Syst, Charlottesville, VA USA
关键词
Methotrexate; intravenous contrast; contrast-induced nephropathy; glucarpidase; acute kidney injury; INDUCED NEPHROPATHY; RISK-FACTORS;
D O I
10.1177/1078155218769126
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methotrexate is a dihydrofolate reductase inhibitor that interferes with DNA synthesis, DNA repair, and cellular replication. We present the first adult case of a patient who received intravenous contrast prior to administration of high-dose methotrexate, who subsequently experienced delayed methotrexate clearance and renal impairment necessitating the use of glucarpidase. This case displays a possible correlation between intravenous radiographic contrast administration and resulting toxicity due to delayed methotrexate clearance.
引用
收藏
页码:993 / 997
页数:5
相关论文
共 50 条
  • [1] GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE TOXICITY
    Ramos Jesus, Ruiz
    Aguado Jorge, Reig
    Cava Paloma, Escobar
    Briz Eduardo, Lopez
    Jose Luis, Poveda Andres
    ATENCION FARMACEUTICA, 2013, 15 (04): : 295 - 298
  • [2] Glucarpidase following high-dose methotrexate: update on development
    Patterson, Daniel M.
    Lee, Siow Ming
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (01) : 105 - 111
  • [3] Impaired high-dose methotrexate clearance: is glucarpidase use conform with current guidelines?
    Pierre, S.
    Bourgue, L.
    Castellan, D.
    Mahe, J.
    Mathieu, O.
    Bihan, K.
    Vial, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 19 - 19
  • [4] Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate
    Schafer, Eric S.
    Bernhardt, M. Brooke
    Reichert, Kate E.
    Haworth, Tara E.
    Shah, Mona D.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : E40 - E42
  • [5] Toxicity associated with high-dose intravenous methotrexate for hematological malignancies
    Wight, Joel
    Ku, Matthew
    Garwood, Melissa
    Carradice, Duncan
    Lasica, Masa
    Keamy, Louise
    Hawkes, Eliza A.
    Grigg, Andrew
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2375 - 2382
  • [6] High-Dose Methotrexate (HDMTX) Induced Nephrotoxicity: Glucarpidase or Dialysis?
    Sridhar, Abhinaya
    Malik, Uzma
    Kapoor, Aromma
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 380 - 380
  • [7] Severe methotrexate toxicity precipitated by intravenous radiographic contrast
    Harned, Theresa M.
    Mascarenhas, Leo
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (07) : 496 - 499
  • [8] Impaired high-dose methotrexate clearance: does glucarpidase use conform with current guidelines?
    Bourgue, Lucile
    Pierre, Sabrina
    Castellan, Delphine
    Mahe, Julien
    Hilaire-Buys, Dominique
    Bihan, Kevin
    Vial, Thierry
    CLINICAL TOXICOLOGY, 2019, 57 (06) : 572 - 572
  • [9] Glucarpidase in high-dose methotrexate delayed elimination: Uncertain effectiveness
    Lepoix, E.
    Azzouz, B.
    Michelet-Huot, E.
    Morel, A.
    Trenque, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 199 - 200
  • [10] Clinical Outcomes in Patients with High-Dose Methotrexate Toxicity Treated with Vs. without Glucarpidase
    Gupta, Shruti
    LaCasce, Ann
    Leaf, Rebecca Karp
    Kaunfer, Sarah
    Leaf, David E.
    BLOOD, 2023, 142